4.7 Article

Cost-Effectiveness of Exercise Therapy in Patients with Intermittent Claudication-A Comparison of Supervised Exercise, Home-Based Structured Exercise, and Walk Advice from the SUNFIT Trial

期刊

JOURNAL OF CLINICAL MEDICINE
卷 12, 期 16, 页码 -

出版社

MDPI
DOI: 10.3390/jcm12165277

关键词

peripheral artery disease; intermittent claudication; exercise therapy; quality-adjusted life-years; cost-effectiveness analysis

向作者/读者索取更多资源

Hospital-based supervised exercise (SEP) is not cost-effective for patients with intermittent claudication (IC) compared to walk advice (WA) with or without home-based structured exercise programs (HSEP). Although the average healthcare cost per patient was similar between WA and HSEP groups, it was significantly higher in the SEP group. The findings suggest that HSEP may have a higher probability of being cost-effective compared to WA, but further research is needed.
Hospital-based supervised exercise (SEP) is a guideline-recommended intervention for patients with intermittent claudication (IC). However, due to the limited availability of SEP, home-based structured exercise programs (HSEP) have become increasingly popular alongside the go home and walk advice. We evaluated the cost-effectiveness of walk advice (WA) with Nordic pole walking vs. SEP combined with WA or HSEP combined with WA. We used data from the SUNFIT RCT (NCT02341716) to measure quality-adjusted life-years (QALYs) over a 12-month follow-up, and economic costs were obtained from a hospital cost-per-patient accounting system. Incremental cost-effectiveness ratios (ICERs) were calculated, and uncertainty was assessed using nonparametric bootstrapping. The average health-care-cost per patient was similar in the WA (EUR 1781, n = 51) and HSEP (EUR 1820, n = 48) groups but higher in the SEP group (EUR 4619, n = 50, p-value < 0.01). Mean QALYs per patient during the follow-up were similar with no statistically significant differences. The findings do not support SEP as a cost-effective treatment for IC, as it incurred significantly higher costs without providing additional health improvements over WA with or without HSEP during the one-year observation period. The analysis also suggested that HSEP may be cost-effective compared to WA, but only with a 64% probability.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据